Viewing Study NCT05650060


Ignite Creation Date: 2025-12-25 @ 2:15 AM
Ignite Modification Date: 2026-03-04 @ 9:54 PM
Study NCT ID: NCT05650060
Status: COMPLETED
Last Update Posted: 2023-04-06
First Post: 2022-12-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module